<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560781</url>
  </required_header>
  <id_info>
    <org_study_id>VA IRB# 01023</org_study_id>
    <nct_id>NCT00560781</nct_id>
  </id_info>
  <brief_title>Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs</brief_title>
  <official_title>Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durham VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durham VA Medical Center</source>
  <brief_summary>
    <textblock>
      This study will test the therapeutic potential of augmenting a stable SSRI regimen with the
      neurosteroid pregnenolone to reduce cognitive symptoms and PTSD symptoms in patients
      diagnosed with PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS, BAC-A</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCL, CD-RISC, CGI, BDI-II</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregnenolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnenolone or Placebo</intervention_name>
    <description>Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-65 years of age, any ethnic group, either sex

          2. DSM-IV diagnosis of PTSD by MINI (see schedule of events)

          3. No change in SSRI medications for &gt; 4 weeks.

          4. No anticipated need to alter any psychotropic medications for the 10-week duration of
             the study.

          5. Ability to fully participate in the informed consent process, or have a legal guardian
             able to participate in the informed consent process.

        Exclusion Criteria:

          1. Unstable medical or neurological illness, including seizures, CVA, prostate or breast
             cancer

          2. Use of oral contraceptives or other hormonal supplementation such as estrogen.

          3. Significant suicidal or homicidal ideation.

          4. Concomitant medications for medical conditions will be addressed on a case-by-case
             base to determine if exclusionary.

          5. Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic
             disorder, or cognitive disorder due to a general medical condition; history of
             substance dependence within the last 3 months

          6. Female patients who are pregnant or breast-feeding.

          7. Known allergy to study medication.

          8. Drugs with a narrow therapeutic index (e.g. thioridazine, mesoridazine, ziprasidone,
             clozapine, etc.) will be excluded, as suggested by the FDA; patients taking these
             agents will not be eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine E Marx, MD MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durham VAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VAMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Pregnenolone</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

